|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
31.22 USD |
-2.32% | +6.92% | +8.14% | |
Published on 06/09/2025 at 17:20
Presenter Speech
Unknown Analyst (Analysts)
All right. Hi, everyone. Thanks for joining us at the Goldman Sachs Annual Healthcare Research Conference. I’m joined by Evert Schimmelpennink who are
|
LENZ Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04:00 PM |
05:20pm |
|
|
LENZ Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09:20 AM |
May. 19 |
|
|
Lotus Pharmaceutical Signs $10 Million Licensing Deal for Presbyopia Drug |
May. 12 |
MT |
|
LENZ Therapeutics, Inc. and Lotus Pharmaceutical Co., Ltd. Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia |
May. 09 |
CI |
|
LENZ Grants Lotus Licensing Rights to Presbyopia Treatment in South Korea, Southeast Asia |
May. 09 |
MT |
|
LENZ Therapeutics, Inc., Q1 2025 Earnings Call, May 07, 2025 |
May. 07 |
|
|
LENZ Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 07 |
CI |
|
LENZ Therapeutics, Inc. – Special Call |
Apr. 15 |
|
|
Lenz Therapeutics Inc Files Of Mixed Shelf Offering Of Up To $500 Million – SEC Filing |
Apr. 04 |
RE |
|
Lenz Therapeutics Inc – Enters Sales Agreement With Td Cowen For $150 Million – SEC Filing |
Apr. 04 |
RE |
|
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from S&P Biotechnology Select Industry Index |
Mar. 23 |
CI |
|
LENZ Therapeutics, Inc., Q4 2024 Earnings Call, Mar 19, 2025 |
Mar. 19 |
|
|
LENZ Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
Mar. 19 |
CI |
|
TD Cowen Initiates LENZ Therapeutics at Buy With $60 Price Target |
Mar. 18 |
MT |
|
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to NASDAQ Biotechnology Index |
Dec. 22 |
CI |
|
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to S&P Biotechnology Select Industry Index |
Dec. 22 |
CI |
|
LENZ Therapeutics, Inc., Q3 2024 Earnings Call, Nov 06, 2024 |
Nov. 06 |
|
|
Earnings Flash (LENZ) LENZ THERAPEUTICS Posts Q3 Loss $-0.38 Per Share |
Nov. 06 |
MT |
|
LENZ Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 |
Nov. 06 |
CI |
|
LENZ Therapeutics, Corxel Pharmaceuticals Say Vision Decline Treatment Met Primary Phase 3 Endpoint |
24-10-28 |
MT |
|
Corxel Pharmaceuticals and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 |
24-10-27 |
CI |
|
Sector Update: Health Care Stocks Slide Monday Afternoon |
24-10-21 |
MT |
|
LENZ Therapeutics Shares Rise After FDA Accepts Application for Potential Eye Condition Treatment |
24-10-21 |
DJ |
|
LENZ Therapeutics Says US FDA Accepts Presbyopia Treatment’s New Drug Application; Shares Rise |
24-10-21 |
MT |
|
LENZ Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia |
24-10-21 |
CI |
LENZ: Dynamic Chart
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
